Bartira Rossi Bergmann *

Autora invitada por SIIC

O tratamento contribui para a descoberta de novas vias mais eficazes de administração de vacinas para a leishmaniose

EFICÁCIA DE VACINAS INTRANASAIS PARA A PREVENÇÃO DA LEISHMANIOSE

Demonstramos que a via intranasal é eficaz para administração de vacinas normalmente exacerbadoras da doença quando administradas por via parenteral, como o antígeno bruto de Leishmania amazonensis e DNA que codifica a proteina LACK. O mecanismo de proteção parece envolver tanto tolerância periférica mas também imunidade ativa mista do tipo TH1 e TH2.

*Bartira Rossi Bergmann
describe para SIIC los aspectos relevantes de su trabajo
INTRANASAL VACCINATION AGAINST CUTANEOUS LEISHMANIASIS WITH A PARTICULATED LEISHMANIAL ANTIGEN OR DNA ENCODING LACK
Institución principal de la investigación
*Instituto de Biofísica Carlos Chagas Filho - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil, Río de Janeiro, Brasil
Imprimir nota

Referencias bibliográficas
1. Bakke H, Lie K, IL Haugen, GE Korsvold, EA Høiby, LM Næss, JHolst, IS Aaberge, F Oftung and B Haneberg. 2001. Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect. Immun. 69:5010–5015.2. Barnes AGC, C Barnfield, R Brew and LS Klavinskis. 2000. Recent developments in mucosal delivery of pDNA vaccines. Curr. Opin. Molec. Therap. 2:87-93.3. Belkaid Y. 2003. The role of CD4+CD25+ regulatory T cells in Leishmania infection. Expert Opin. Biol.Ther. 3:875-885.4. Campbell M, H Diao, JX Ji and L Soong. 2003. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis. Infect. Immun. 71:6270-6278.5. Chen LH, J Wang, A Zganiacz and Z Xing. 2004. Single intranasal mucosal Mycobactetium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 72:238-246.6. Croft SL and GH Coombs. 2003. Leishmaniasis- current chemotherapy and recent advances in the search for novel drugs. Trends in Parasitol. 19:502-508.7. Czerkinsky C, FAnjuere, JR McGhee, A George-Chandy, J Holmgren, M Kieny, K Fujiyashi, JF Mestecky, V Pierrefite-Carle, C Rask and J Sun. 1999. Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170:197-222.8. Dhaliwal JS and FY Liew. 1987. Induction of delayed-type hypersensitivity to Leishmania major and the concomitant acceleration of disease development in progressive murine cutaneous leishmaniasis. Infect. Immun. 55:645-651.9. Dumonteil E, RSM Jesus, EO Javier and GMM del Rosario. 2003. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 21:2161-2168.10. Fujihashi K, T Koga, FW van Ginkel, Y Hagiwara and JR McGhee. 2002. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine; 20:2431-2438.11. Gonzalez-Aseguinolaza G, S Taladriz, A Marquet and V Larraga. 1999. Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum. Eur. J. Biochem. 259:909-916.12. Gurunathan S, DL Sacks, DR Brown, SL Reiner, H Charest, N Glaichenhaus and RA Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-47.13. Hamann A, DP Andrew, D Jablonskiwestrich, B Holzmann and EC Butcher. 1994. Role of alpha (4)-integrins in lymphocyte homing to mucosal tissues in-vivo. J. Immunol. 152:3282-3293.14. Handman E. 2001. Leishmaniasis: Current status of vaccine development. Clin. Microbiol. Rev. 14:229–243.15. Jones DE, MR Ackermann, U Wille, CA Hunter and Scott P. 2002. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect. Immun. 70:2151-2158.16. Julia V, M Rassoulzadegan and N Glaichenhaus. 1996. Resistance to Leishmania major induced by tolerance to a single antigen. Science 274:421-423.17. Julia V, SS McSorley, L Malherbe, JP Breittmayer, F Girard-Pipau, A Beck and N Glaichenhaus. 2000. Priming by microbial antigens from the intestinal flora determines the ability of CD4(+) T cells to rapidly secrete IL-4 in BALB/c mice infected with Leishmania major. J. Immunol. 165:5637-5645.18. Kaiserlian D and N Etchart. 1999. Entry sites for oral vaccines and drugs: A role for M cells, enterocytes and dendritic cells Semin Immunol. 11:217-24.19. Kenney RT, DL Sacks, JP Sypek, L Vilela, AA Gam and K Evans-Davis. 1999. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163:4481-4488.20. Launois P, I Maillard, S Pingel, KG Swihart, I Xenarios, H Acha-Orbea, H Diggelmann, RM Locksley, HR MacDonald and JA Louis. 1997. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6:541-549.21. Liew FY, C Hale and JG Howard. 1985. Prophylactic immunization against experimental leishmaniasis. IV.Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J. Immunol. 135:2095-2101.22. Lira R, S Sundar, A Makharia, R Kenney, A Gam, E Saraiva and D Sacks. 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180:564-567.23. Makala LHC, Y Nishikawa, N Suzuki and H Nagasawa. 2004. Immunology - Antigen-presenting cells in the gut. J. Biomed. Sci. 11:130-141.24. Marzochi KBF, MCA Marzochi, AF Silva, N Grativol, R Duarte, EM Conort and F Modabber. 1998. Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil. Mem Inst Oswaldo Cruz 93:205-212.25. McCluskie MJ and HL Davis. 1998 CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 161:4463-6.26. McSorley SJ, C Rask, R Pichot, V Julia, C Czerkinsky and N Glaichenhaus. 1998. Selective tolerization of Th1-like cells after nasal administration of a cholera toxoid-LACK conjugate. Eur. J. Immunol. 28:424-432.27. Melby PC, J Yang, W Zhao, LE Perez and J Cheng. 2001. Leishmania donovani p36(LACK) DNA Vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:4719-4725.28. Mendez A, Y Belkaid, RA Seder and D Sacks. 2002. Optimisation of DNA vaccination against cutaneous leishmaniasis. Vaccine 20:3702-3708.29. Mosmann TR and S Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138-146.30. Oh YK, JP Kim, TS Hwang, JJ Ko, JM Kim, JS Yang and CK Kim. 2001. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine 19:4519-4525.31. Okuno T, M Takeuchi, Y Matsumoto, H Otsuka and Y Matsumoto. 2002. Pretreatment of Leishmania homologue of receptors for activated C kinase (LACK) promotes disease progression caused by Leishmania amazonensis. Exp. Animals 51:335-341.32. Pinto EF, MM Cortezia and B Rossi-Bergmann. 2003. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis. Vaccine 21:3534-3541.33. Pompeu MML, C Brodskyn, MJ Teixeira, J Clarencio, J Van Weyenberg, ICB Coelho, SA Cardoso, A Barral, M Barral-Netto. 2001. Differences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers. Infec. Immun. 69:7453-7460.34. Ramiro MJ, JJ Zarate, T Hanke, D Rodriguez, JR Rodriguez, M Esteban, J Lucientes, JA Castillo and V Larraga. 2003. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21:2474-84.35. Reiner SL and RM Locksley. 1995. The regulation of immunity to Leishmania major. Ann. Rev. Immunol. 13:151-177.36. Rossi-Bergmann B, A Lenglet, CR Bezerra-Santos, D Costa-Pinto and YM Traub-Czeko. 1999. Use of fluorescent Leishmania for faster quantitation of parasite growth in vitro and in vivo. Mem. I. Oswaldo Cruz 94 (Suppl. II):74.37. Shah JA, PA Darrah, DR Ambrozak, TN Turon, S Mendez, J Kirman, CY Wu, N Glaichenhaus and RA Seder. 2003. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J. Exp. Med. 198:281-291.38. World Health Organization/TDR. Tropical Diseases Research - Leishmaniasis. Fourteen Programme Report. 1999:22.39. Xu D and FY Liew. 1994. Genetic vaccination against leishmaniasis. Vaccine 12:1534-1536.

Otros artículos de Bartira Rossi Bergmann

Torres-Santos EC; Da-Silva SAG; Santos APPT; Almeida AP; Costa SS and Rossi-Bergmann B. (2003) Toxicological analysis and effectiveness of oral Kalanchoe pinnata on a human case of leishmaniasis. Phytotherapy Research. 17(7):801-803.Pinto EF; Cortezia MM and Rossi-Bergmann B. (2003) Interferon-gamma - inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis. Vaccine 21:3534-3541.Costa MAC; Barata LEB; Rossi-Bergmann B and Takahata Y. (2003). Pattern recognition and neural networks applied to structure-activity relationships of neolignans tested against Leishmania amazonensis using quantum chemical and topological descriptors. International Journal of Quantum Chemistry vol 95(3):295-302.Rossi-Bergmann B, Falcão CAB; Lenglet A; Bezerra-Santos CR; Costa-Pinto D and Traub-Czeko. (1999) A simple fluorimetric method for assessing drug and vaccine efficacy in cutaneous leishmaniasis using Leishmania amazonensis expressing Green Fluorescence Protein. Mem. I. Oswaldo Cruz 94 (Suppl. II):74.Pinheiro RO, Fentanes RF; Lopes JRC and Rossi-Bergmann B. (2003). TGF--associated aggravation of cutaneous leishmaniasis after immunization of BALB/c mice with a Leishvacin®-like vaccine. (Vaccine, submetido).CR Bezerra-Santos, FMP Balestieri, B Rossi-Bergmann, LMT Peçanha, MR Piuvezam (2003) Cissampelos sympodialis EICHL. (Menispermaceae): oral treatment decreases IgE levels and induces a TH1-skewed cytokine production in actively sensitized mice. Journal of Ethnopharmacology, 93(1): (in press).Demicheli C, Ochoa R, Silva JBB, Falcão CAB, Rossi-Bergmann B, Melo AL, Sinisterra, RD and Frezard F. (2004) Oral delivery of meglumine antimoniate using beta-cyclodextrin for the treatment of leishmaniasis. Antimicrobial Agents and Chemotherapy 48(1):100-103.Torres-Santos EC; Lopes D; Oliveira RR; Carauta JPP; Falcão CAB; Kaplan MAC and Rossi-Bergmann B. (2004) Structure - activity relationship of triterpenoids from Pourouma guyanensis with antileishmanial activity. Phytomedicine 11(2-3):114-120.Pinheiro RO; Pinto EF; Benedito AB; Lopes UG and Rossi-Bergmann B. (2004). The T-cell anergy induced by Leishmania amazonensis antigens is related with apoptosis and defective antigen presentation. Anais da Academia Brasileira de Ciências, vol 76(3):519-527.

Para comunicarse con Bartira Rossi Bergmann mencionar a SIIC como referencia:

---

Acerca del trabajo completo

EFICÁCIA DE VACINAS INTRANASAIS PARA A PREVENÇÃO DA LEISHMANIOSE

Título original en castellano
VACINAÇÃO INTRANASAL CONTRA A LEISHMANIOSE CUTÂNEA COM UM ANTIGENO PARTICULADO DE LEISHMANIA OU COM DNA CODIFICANDO LACK

Autor
Bartira Rossi Bergmann¹
1 Biomédica, Universidade Federal do Rio de Janeiro, Professora Adjunta

Acceso a la fuente original
Infection and Immunity
http://iai.asm.org

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades